Cannovum AG significantly increased both sales and customers in its medical cannabis business in H1 2022.
Berlin, 07th September 2022. Cannovum AG, one of the market leaders in the medical cannabis industry, significantly increased both sales and customers in its medical cannabis business in H1 2022. Cannovum AG continues to make progress towards opening the market for over-the-counter cannabis in Germany.
Cannovum achieved revenues of 516952 Euros in its operating business (1 HY 2022), an increase of 1231 percent compared to the same period in the previous year (38829 euros). Pia Marten, CEO Cannovum AG: “Our strategy to win the trust of physicians and pharmacists with premium products exceeded our expectations. We are well within our plans in terms of sales growth and new customer acquisition.”
Cannovum only sells products that meet the highest pharmaceutical standards. "We continue to make an important contribution to supplying the German market with high-quality cannabis,"says Marten.
This strong commitment to quality is well received. Already more than 300 and thus more than every 10th pharmacy supplying cannabis is a regular customer of Cannovum.
Cannovum's success is also attributed to its professional and experienced sales force, which supports doctors and local pharmacies. In light of the upcoming legalization of cannabis, a focus will be on the cooperation with pharmacies as an essential distribution channel.
For more information about Cannovum AG and Cannovum Health eG, in which the operating business with medical cannabis of Cannovum AG is consolidated, please visit:https://cannovum.de/investor-relations
Cannovum AG is the first German listed cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through itssubsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.
For more information, visit www.cannovum.com
Klaus Madzia, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, firstname.lastname@example.org
Cannovum AG enters into a partnership with WEECO Pharma GmbH. As of today, Cannovum will include WEECO's products in its portfolio, taking another important step towards becoming a full-service cannabis provider.
Cannovum AG expands its Management Board. The new board position of the first German fully licensed cannabis company on the stock exchange will be taken over by Klaus Madzia as of 25.11.2022.
Cannovum AG, the first German fully licensed cannabis company on the stock exchange, will move on Dec. 1st 2022 from the Open Market to the "Primary Market" segment of the Düsseldorf Stock Exchange.